The NHS England revealed that it will be providing a drug to hundreds of women suffering from advanced cervical cancer which could extend their lives by as much as four months.
Avastin, or bevacizumab, is yet to get a license for treating cervical cancer but the drug will be available to patients through the Cancer Drugs Fund after a number of oncologists requested access to the drug while studies have shown it to be effective in increasing the survival period of the cancer patients.
The drug is already being used in treating a number of other cancers, including breast, lung, bowel, ovarian and kidney cancers, and England will be the first country to offer it for cervical cancer patients.
"This new addition to the list demonstrates NHS England's commitment to achieving maximum benefit to patients from the £200 million Cancer Drugs Fund. The process of updating the list is led by cancer specialists, and should ensure that patients benefit quickly when new drugs become available that are backed by good evidence from trial data", Professor Peter Clark, Chair of the Chemotherapy CRG, said.